Macronutrients and Gut Hormone Secretion
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Study hypothesis is to examine the relative contribution of macronutrients for gut hormone secretion after a mixed meal in healthy volunteers and in subjects with type 2 diabetes. Individual macronutrients or a mixed meal will therefore be served and gut hormones are measured during the following 300 min.
| Condition | Intervention |
|---|---|
|
Type 2 Diabetes |
Other: Macronutrients |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Factorial Assignment Masking: Open Label |
| Official Title: | Effects of Macronutrients on Gut Hormone and Islet Hormone Secretion in Healthy Volunteers and Type 2 Diabetes |
- Release of gut hormones [ Time Frame: 300 min ] [ Designated as safety issue: No ]
- Insulin secretion [ Time Frame: 300 min ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 36 |
| Study Start Date: | September 2011 |
| Estimated Study Completion Date: | March 2013 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Type 2 diabetes
Administration of macronutrients in type 2 diabetes
|
Other: Macronutrients
Glucose 330 kcal Protein 110 kcal Fat emulsion 110 kcal Mixed meal 550 kcal
Other Names:
|
|
Experimental: Healthy volunteers
Administration of macronutrients in healthy volunteers
|
Other: Macronutrients
Glucose 330 kcal Protein 110 kcal Fat emulsion 110 kcal Mixed meal 550 kcal
Other Names:
|
Detailed Description:
In healthy volunteers and subjects with dietary regulated diabetes mellitus, glucose, protein mixture or fat emulsion will be served individually and on a separate occasions a mixed meal will be served. Samples will be taken during the following 300 min. Concentrations of the gut hormones glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1, insulin and glucagon will be determined.
Eligibility| Ages Eligible for Study: | 35 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy status or type 2 diabetes with dietary regulation
Exclusion Criteria:
- Liver disease
- kidney disease
- thyroid disease
Contacts and Locations| Sweden | |
| Department of Clinical Sciences Lund, Lund University | Not yet recruiting |
| Lund, Sweden, 221 84 | |
| Contact: Bo Ahrén, PhD 46462220758 Bo.Ahren@med.lu.se | |
| Principal Investigator: Bo Ahrén, PhD | |
| Lund University | Recruiting |
| Lund, Sweden, 22184 | |
| Contact: Bo Ahrén, MD +46462220758 Bo.Ahren@med.lu.se | |
| Principal Investigator: Bo Ahrén, MD | |
| Principal Investigator: | Bo Ahrén, PhD | Lund University |
More Information
No publications provided
| Responsible Party: | Bo Ahren, Professor, Lund University |
| ClinicalTrials.gov Identifier: | NCT01366794 History of Changes |
| Other Study ID Numbers: | 005 |
| Study First Received: | May 31, 2011 |
| Last Updated: | October 9, 2012 |
| Health Authority: | Sweden: Medical Products Agency |
Keywords provided by Lund University:
|
Gut hormones Insulin secretion |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 22, 2013